vs
American Well Corp（AMWL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
American Well Corp的季度营收约是REGENXBIO Inc.的1.8倍（$55.3M vs $30.3M），American Well Corp净利率更高（-45.1% vs -221.3%，领先176.3%），REGENXBIO Inc.同比增速更快（43.0% vs -22.1%），American Well Corp自由现金流更多（$-17.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -3.6%）
美国烟草公司由J.B.杜克于1890年整合多家美国烟草制造商合并创立，1896年成为道琼斯工业平均指数最初的12支成分股之一。该公司收购了好彩公司及超过200家竞争对手，一度垄断美国烟草行业。1907年美国联邦政府发起反垄断诉讼，最终将该公司分拆为多家企业。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
AMWL vs RGNX — 直观对比
营收规模更大
AMWL
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出65.1%
-22.1%
净利率更高
AMWL
高出176.3%
-221.3%
自由现金流更多
AMWL
多$35.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.3M | $30.3M |
| 净利润 | $-24.9M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -45.5% | -190.0% |
| 净利率 | -45.1% | -221.3% |
| 营收同比 | -22.1% | 43.0% |
| 净利润同比 | 41.6% | -31.2% |
| 每股收益（稀释后） | $-1.53 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMWLRGNX
| Q4 25 | $55.3M | $30.3M | ||
| Q3 25 | $56.3M | $29.7M | ||
| Q2 25 | $70.9M | $21.4M | ||
| Q1 25 | $66.8M | $89.0M | ||
| Q4 24 | $71.0M | $21.2M | ||
| Q3 24 | $61.0M | $24.2M | ||
| Q2 24 | $62.8M | $22.3M | ||
| Q1 24 | $59.5M | $15.6M |
净利润AMWLRGNX
| Q4 25 | $-24.9M | $-67.1M | ||
| Q3 25 | $-32.4M | $-61.9M | ||
| Q2 25 | $-19.7M | $-70.9M | ||
| Q1 25 | $-18.7M | $6.1M | ||
| Q4 24 | $-42.7M | $-51.2M | ||
| Q3 24 | $-43.5M | $-59.6M | ||
| Q2 24 | $-49.9M | $-53.0M | ||
| Q1 24 | $-72.1M | $-63.3M |
毛利率AMWLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率AMWLRGNX
| Q4 25 | -45.5% | -190.0% | ||
| Q3 25 | -52.1% | -176.3% | ||
| Q2 25 | -28.7% | -296.3% | ||
| Q1 25 | -45.5% | 13.6% | ||
| Q4 24 | -60.2% | -242.1% | ||
| Q3 24 | -77.6% | -256.6% | ||
| Q2 24 | -83.4% | -251.3% | ||
| Q1 24 | -126.1% | -408.8% |
净利率AMWLRGNX
| Q4 25 | -45.1% | -221.3% | ||
| Q3 25 | -57.5% | -208.3% | ||
| Q2 25 | -27.8% | -331.8% | ||
| Q1 25 | -28.0% | 6.8% | ||
| Q4 24 | -60.1% | -241.3% | ||
| Q3 24 | -71.2% | -246.3% | ||
| Q2 24 | -79.5% | -237.7% | ||
| Q1 24 | -121.1% | -405.4% |
每股收益（稀释后）AMWLRGNX
| Q4 25 | $-1.53 | $-1.30 | ||
| Q3 25 | $-2.00 | $-1.20 | ||
| Q2 25 | $-1.24 | $-1.38 | ||
| Q1 25 | $-1.19 | $0.12 | ||
| Q4 24 | $-2.71 | $-0.99 | ||
| Q3 24 | $-2.87 | $-1.17 | ||
| Q2 24 | $-3.36 | $-1.05 | ||
| Q1 24 | $-4.94 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $182.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $235.6M | $102.7M |
| 总资产 | $323.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMWLRGNX
| Q4 25 | $182.3M | $230.1M | ||
| Q3 25 | $200.9M | $274.2M | ||
| Q2 25 | $219.1M | $323.3M | ||
| Q1 25 | $222.4M | $267.9M | ||
| Q4 24 | $228.3M | $234.7M | ||
| Q3 24 | $244.6M | $255.5M | ||
| Q2 24 | $276.9M | $290.4M | ||
| Q1 24 | $308.6M | $338.7M |
股东权益AMWLRGNX
| Q4 25 | $235.6M | $102.7M | ||
| Q3 25 | $254.9M | $161.5M | ||
| Q2 25 | $282.6M | $213.7M | ||
| Q1 25 | $294.0M | $274.2M | ||
| Q4 24 | $304.8M | $259.7M | ||
| Q3 24 | $336.7M | $301.4M | ||
| Q2 24 | $363.9M | $348.3M | ||
| Q1 24 | $408.7M | $390.7M |
总资产AMWLRGNX
| Q4 25 | $323.8M | $453.0M | ||
| Q3 25 | $359.4M | $525.2M | ||
| Q2 25 | $388.7M | $581.0M | ||
| Q1 25 | $419.5M | $490.9M | ||
| Q4 24 | $436.0M | $466.0M | ||
| Q3 24 | $483.0M | $519.1M | ||
| Q2 24 | $507.8M | $569.4M | ||
| Q1 24 | $548.4M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-17.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-17.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | -31.4% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流AMWLRGNX
| Q4 25 | $-17.4M | $-52.3M | ||
| Q3 25 | $-18.8M | $-56.0M | ||
| Q2 25 | $-4.7M | $-49.3M | ||
| Q1 25 | $-25.1M | $33.6M | ||
| Q4 24 | $-13.4M | $-31.6M | ||
| Q3 24 | $-32.4M | $-40.5M | ||
| Q2 24 | $-21.8M | $-45.5M | ||
| Q1 24 | $-59.8M | $-55.5M |
自由现金流AMWLRGNX
| Q4 25 | $-17.4M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $-25.1M | $32.6M | ||
| Q4 24 | $-13.4M | $-32.7M | ||
| Q3 24 | $-32.4M | $-40.9M | ||
| Q2 24 | $-21.8M | $-46.0M | ||
| Q1 24 | $-59.8M | $-56.0M |
自由现金流率AMWLRGNX
| Q4 25 | -31.4% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | -37.6% | 36.6% | ||
| Q4 24 | -18.9% | -154.2% | ||
| Q3 24 | -53.0% | -168.9% | ||
| Q2 24 | -34.7% | -206.2% | ||
| Q1 24 | -100.5% | -358.5% |
资本支出强度AMWLRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.1% | 3.6% |
现金转化率AMWLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMWL
| Platform Subscription | $28.8M | 52% |
| Visits | $23.7M | 43% |
| Others | $2.8M | 5% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
